Sex and cardiovascular disease status differences in attitudes and willingness to participate in clinical research studies/clinical trials

Published on May 30, 2018in Trials1.883
· DOI :10.1186/S13063-018-2667-7
Thomas S. Gruca2
Estimated H-index: 2
(UI: University of Iowa),
Thomas S. Gruca23
Estimated H-index: 23
(UI: University of Iowa)
+ 2 AuthorsGary E. Rosenthal68
Estimated H-index: 68
(Wake Forest University)
Sources
Abstract
While women are under-represented in research on cardiovascular disease (CVD), little is known about the attitudes of men and women with CVD regarding participation in clinical research studies/clinical trials. Patients with CVD (and/or risk factors) and patients with other chronic conditions from Iowa were recruited from a commercial panel. An on-line survey assessed willingness to participate (WTP) and other attitudes towards aspects of clinical research studies. Based on 504 respondents, there were no differences in WTP in patients with CVD compared to patients with other chronic diseases. Across all respondents, men had 14% lower WTP (relative risk (RR) for men, 0.86, 95% CI, 0.72–1.02). Among patients with CVD, there was no significant difference in WTP between women (RR for women = 1) and men (RR for men, 0.96, 95% CI, 0.82–1.14). There were no significant differences based on sex or CVD status for attitudes on randomization, blinding, side effects, conflict of interest, experimental treatments or willingness to talk to one’s physician. Women had more favorable attitudes about participants being treated like “guinea pigs” (RR for men, 0.84, 95% CI, 0.73–0.98) and clinical trials being associated with terminally ill patients (RR for men, 0.93, 95% CI, 0.86–1.00). The findings reported here suggest that the observed lower levels of participation by women are due to factors other than a lower WTP or to women having more negative attitudes towards aspects of study participation. Patients with CVD have similar attitudes and WTP as patients with other chronic conditions.
References36
Newest
#1Christine ButtorffH-Index: 9
#2Teague RuderH-Index: 3
Last. Melissa BaumanH-Index: 2
view all 3 authors...
This chartbook updates previous versions with more recent data on the prevalence of multiple chronic conditions (2008–2014) and associated health care utilization and spending. It also analyzes functional and other limitations for those with multiple chronic conditions.
176 CitationsSource
#1Melonie P. HeronH-Index: 1
This report presents final 2013 data on the 10 leading causes of death in the United States by age, sex, race, and Hispanic origin. Leading causes of infant, neonatal, and postneonatal death are also presented. This report supplements "Deaths: Final Data for 2013," the National Center for Health Statistics’ annual report of final mortality statistics.Data in this report are based on information from all death certificates filed in the 50 states and the District of Columbia in 2013. Causes of dea...
87 Citations
#1Rebecca J. Williams (NIH: National Institutes of Health)H-Index: 8
#2Tony Tse (NIH: National Institutes of Health)H-Index: 24
Last. Deborah A. Zarin (NIH: National Institutes of Health)H-Index: 27
view all 4 authors...
Background Clinical trials that end prematurely (or “terminate”) raise financial, ethical, and scientific concerns. The extent to which the results of such trials are disseminated and the reasons for termination have not been well characterized. Methods and Findings A cross-sectional, descriptive study of terminated clinical trials posted on the ClinicalTrials.gov results database as of February 2013 was conducted. The main outcomes were to characterize the availability of primary outcome data o...
78 CitationsSource
#1Meryl S. Cohen (UPenn: University of Pennsylvania)H-Index: 43
As the congenital heart disease population ages, coronary artery disease may emerge as a significant comorbidity. This presents a new problem to cardiologists caring for an aging population that did not previously exist. Various congenital heart defects are likely at higher risk for the development of coronary artery disease including congenital coronary artery anomalies, defect with abnormal coronary artery connections to the ventricles, and conotruncal anomalies that require coronary artery re...
5 CitationsSource
#1Lan Shen (Duke University)H-Index: 1
#2Chiara Melloni (Duke University)H-Index: 27
Cardiovascular disease (CVD) is the leading cause of mortality in women. Differences in pathophysiology, diagnosis, and treatment of women with cardiovascular disease compared with men have become a major focus during the past decades. Guideline of CVD prevention in women drew heavily on the results of randomized clinical trials (RCT). However, data from RCT in women was limited, leading to concerns of women been underrepresented in clinical trials from which guidelines were generated. During th...
7 CitationsSource
#1Benjamin M. Craig (USF: University of South Florida)H-Index: 24
#2Ron D. HaysH-Index: 152
Last. Bryce B. ReeveH-Index: 74
view all 6 authors...
Background: Despite the increasing use of panel surveys, little is known about the differences in data quality across panels. Objective: The aim of this study was to characterize panel survey companies and their respondents based on (1) the timeliness of response by panelists, (2) the reliability of the demographic information they self-report, and (3) the generalizability of the characteristics of panelists to the US general population. A secondary objective was to highlight several issues to c...
55 CitationsSource
#1Sharon McCann (Aberd.: University of Aberdeen)H-Index: 9
#2Marion K Campbell (Aberd.: University of Aberdeen)H-Index: 70
Last. Vikki Entwistle (Aberd.: University of Aberdeen)H-Index: 61
view all 3 authors...
ObjectivesRandomized controlled trials are important for evaluating health care interventions, but recruitment can be difficult. Studies of potential participants’ perspectives on trial participation are accumulating, but their collective contribution is not obvious. In 2007, we conducted a meta-ethnographic synthesis of people’s reasons for accepting or declining participation. This paper reports a second synthesis, conducted separately on the same topic, using studies published subsequently. I...
35 CitationsSource
#1Seth S. Martin (Johns Hopkins University)H-Index: 50
#2Fang-Shu Ou (UNC: University of North Carolina at Chapel Hill)H-Index: 28
Last. Tracy Y. Wang (Duke University)H-Index: 69
view all 7 authors...
Objectives The purpose of this study was to quantitatively examine the association of patient- and trial-specific factors with participation in cardiovascular randomized clinical trials. Background Randomized clinical trials are central to evidenced-based medicine, but low patient participation rates and potentially modifiable barriers are not well understood. Methods At a large U.S. academic health system, we examined screening logs from December 1, 2005, to February 28, 2011, from 15 cardiovas...
51 CitationsSource
#1Robin L. Kruse (MU: University of Missouri)H-Index: 33
#2Richelle J. KoopmanH-Index: 30
Last. David R. MehrH-Index: 47
view all 7 authors...
BACKGROUND AND OBJECTIVES: Internet-based technologies such as personal health records and patient portals are increasingly viewed as essential for enhancing patient-provider communication and patient-centered care. We examined how primary care patients use the Internet, particularly patient characteristics associated with Internet use. METHODS: We surveyed patients in five primary care clinic waiting rooms. Patients who had used email or the Internet in the past month (Internet users) were aske...
54 Citations
#1Lori Mosca (AHA: American Heart Association)H-Index: 17
#2Emelia J. Benjamin (AHA: American Heart Association)H-Index: 47
Last. Nanette K. Wenger (AHA: American Heart Association)H-Index: 94
view all 37 authors...
Substantial progress has been made in the awareness, treatment, and prevention of cardiovascular disease (CVD) in women since the first women-specific clinical recommendations for the prevention of CVD were published by the American Heart Association (AHA) in 1999.1 The myth that heart disease is a “man’s disease” has been debunked; the rate of public awareness of CVD as the leading cause of death among US women has increased from 30% in 1997 to 54% in 2009.2 The age-adjusted death rate resultin...
1,597 CitationsSource
Cited By3
Newest
#1Jeske J. K. van Diemen (VU: VU University Amsterdam)H-Index: 2
#2Petra Verdonk (VU: VU University Amsterdam)H-Index: 19
Last. Yolande Appelman (VU: VU University Amsterdam)H-Index: 14
view all 9 authors...
Source
This study assessed to what extent women were included in all phases of drug development; whether the clinical studies in the marketing authorization application dossiers include information per sex; and explored whether there are differences between women and men in the drugs' efficacy and safety. Data were extracted from dossiers submitted to the European Medicines Agency. Twenty-two dossiers of drugs approved between 2011 and 2015 for the treatment of various diseases were included. Female an...
Source
#1Yong K. Choi (UC Davis: University of California, Davis)H-Index: 1
#2Javier López (UC Davis: University of California, Davis)H-Index: 23
view all 6 authors...
: The willing participation of patients in clinical research is a critical element in national efforts to collect health data for precision medicine and large cohort studies. However, recruiting patients is challenging. Clinical data research networks (CDRN) have primarily been used for observational studies, but may be able to enhance recruitment efforts. We need a better understanding of patient motivation and preferences for research participation and their interest in different types of rese...